Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-29

E2F3 - a potential clinical marker for prostate cancer

Objectif

Prostate cancer is now the leading cause of cancer related deaths in most European countries. However, knowledge of the underlying mechanisms is still scarce. The overall aim of this project is to identify new oncogenes involved in prostate cancer and assess their potential as clinical markers. The focus will be the E2F3 transcription factor that has an established role in cell cycle progression and has recently been proposed as a candidate oncogene for bladder cancer. Initial studies indicate that 70% of prostate cancers over-express E2F3.

We will combine tissue microarray (TMA) staining data from 1200 prostate cancer patients with clinical data, and statistically analyse the correlation. We will also test the hypothesis that down regulation of pBR is needed for upregulation of E2F3 to have an impact, by studies of the pBR levels in parallel with the E2F3 analysis on the TMAs. We will determine whether the upregulation is associated with increased copy number of the gene by flourescence in situ hybridisation ( FISH) onto TMAs and, finally, the biological role of E2F3 in the development of prostate cancer will be investigated by siRNA technology in prostate cancer cell lines that over-express E2F3.

Champ scientifique (EuroSciVoc)

Thème(s)

Appel à propositions

FP6-2002-MOBILITY-5
Voir d’autres projets de cet appel

Régime de financement

EIF - Marie Curie actions-Intra-European Fellowships

Coordinateur

INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Contribution de l’UE
Aucune donnée
Coût total
Aucune donnée